Sign in

    Jim Desborough

    Research Analyst at Private Investor

    Jim Desborough's questions to PURE BIOSCIENCE (PURE) leadership

    Jim Desborough's questions to PURE BIOSCIENCE (PURE) leadership • Q4 2018

    Question

    Jim Desborough, a Private Investor, inquired about PURE's cash position, asking if the company had enough funds to operate through Q3 2019 or if another financing round would be necessary. He also asked for the specific monthly revenue run rate required to achieve cash flow breakeven.

    Answer

    CEO Hank Lambert explained that based on current revenue projections and cash on hand, the company expects to reach cash flow breakeven by the end of calendar Q1 2019 without additional financing. However, he conceded a small financing might be needed if revenue growth is slower than projected. Lambert also clarified that due to significant cost-cutting measures, the breakeven revenue run rate has been reduced from a prior $10-$12 million to approximately $6 million, which equates to $500,000 in monthly revenue.

    Ask Fintool Equity Research AI